STOCK TITAN

Kenvue Inc. SEC Filings

KVUE NYSE

Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

This page provides access to Kenvue Inc. (NYSE: KVUE) SEC filings, giving investors a primary source for the company’s regulatory disclosures. As the world’s largest pure-play consumer health company by revenue, Kenvue uses its SEC reports to detail financial performance, risk factors, governance matters and significant corporate events related to its portfolio of brands such as Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Tylenol® and Zyrtec®.

Among the most important documents for KVUE are current reports on Form 8-K. In 2025, Kenvue filed several 8-Ks to furnish quarterly earnings press releases and to describe leadership changes, preliminary financial results and the Board’s comprehensive review of strategic alternatives. A key 8-K filed on November 3, 2025 outlines an Agreement and Plan of Merger with Kimberly-Clark Corporation, under which a Kimberly-Clark subsidiary will merge with and into Kenvue and Kenvue will ultimately become part of a wholly owned Kimberly-Clark subsidiary. That filing explains the merger structure, the cash and stock consideration for each share of Kenvue common stock, conditions to closing, and termination and fee provisions.

Investors can also use Kenvue’s filings to understand how management presents non-GAAP financial measures. The company’s 8-K earnings materials define metrics such as Adjusted gross profit margin, Adjusted operating income and margin, Adjusted net income, Adjusted diluted earnings per share, Adjusted EBITDA margin, Adjusted effective tax rate, Free cash flow and Organic sales, and reconcile them to the most comparable U.S. GAAP measures. These disclosures clarify how Kenvue evaluates operating efficiency, profitability and cash generation over time.

On this page, Stock Titan surfaces Kenvue’s SEC submissions as they are made available on EDGAR and pairs them with AI-powered summaries to explain the key points in plain language. Users can quickly scan new 10-K and 10-Q reports when filed, review 8-Ks for material events such as the Kimberly-Clark merger agreement or leadership transitions, and examine any proxy materials related to shareholder votes. This combination of real-time filings access and AI explanations helps investors follow how regulatory disclosures may affect KVUE shareholders and the future of the Kenvue business within the consumer health sector.

Rhea-AI Summary

Kenvue Inc. (KVUE) Chief Operations Officer reported routine equity compensation activity. On 11/18/2025, restricted stock units converted into 494 shares of common stock and a separate award converted into 166 shares, both on a one-for-one basis upon vesting. To cover FICA taxes related to retirement eligibility, 494 and 166 shares were withheld at a price of $14.37 per share.

After these transactions, the officer beneficially owned 64,441.23 shares of Kenvue common stock directly, along with 12,074.85 restricted stock units from one award and 15,485.69 restricted stock units from another. These RSU awards are scheduled to vest in three equal annual installments on specific dates in 2025, 2026, 2027, and 2028, subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Kenvue Inc. filed an initial ownership report for a senior executive showing no current holdings of company stock. The filing is a Form 3 for Kenvue Inc. (ticker KVUE) related to an event dated 11/17/2025.

The reporting person is identified as an officer of Kenvue, serving as Chief Digital & Marketing Officer, and is filing individually rather than as part of a group. In the accompanying ownership tables, the report states that no securities are beneficially owned, covering both non-derivative and derivative securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Kimberly-Clark Corporation filed a communication under Rule 425 describing a proposed transaction with Kenvue Inc. and the related shareholder approval process. Kimberly-Clark plans to file a registration statement on Form S-4 covering the proposed issuance of its common stock, which will include a joint proxy statement/prospectus to be mailed to both companies’ stockholders for votes on transaction-related proposals after SEC effectiveness. The communication emphasizes that it is not an offer to sell or buy securities and urges investors to read carefully the registration statement, joint proxy statement/prospectus, and related SEC filings when available. It also highlights that projections and other statements about expected benefits, synergies, financing, cash flow, and timing are forward-looking and subject to significant risks and uncertainties outlined in each company’s SEC reports.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
merger
Rhea-AI Summary

Kenvue shared employee FAQs about its proposed transaction with Kimberly‑Clark, outlining how pay, benefits, time off, performance reviews, bonuses and long‑term incentives would be handled around closing. Equity awards will convert on a value‑for‑value basis: RSUs to Kimberly‑Clark RSUs, stock options to Kimberly‑Clark options with exercise price and count adjusted to maintain value, and PSUs to Kimberly‑Clark RSUs using the greater of actual or target performance (illustrated with a $10,000 example).

The FAQs state that eligible employees involuntarily terminated before closing receive severance under their current plan, and those terminated on or after closing and before the first anniversary receive the better of Kenvue’s or Kimberly‑Clark’s plan. The communication also notes that Kimberly‑Clark will file a Form S‑4 with a joint proxy statement/prospectus to be mailed after SEC effectiveness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
merger
-
Rhea-AI Summary

T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting a passive stake in Kenvue Inc. (KVUE). The firm beneficially owns 115,533,086 shares of common stock, representing 6.0% of the class as of the event date 09/30/2025.

The filer reports 110,837,001 shares with sole voting power and 115,243,402 shares with sole dispositive power, with zero shared voting or dispositive power. The reporting person is classified as an investment adviser (IA) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Kimberly-Clark Corporation has issued a communication describing a proposed transaction with Kenvue Inc., in which the two companies plan to combine to create what they describe as a preeminent global health and wellness leader. The message comes from a senior Kimberly-Clark executive, who characterizes this as one of the most important days in the company’s history and highlights the strategic significance of joining two iconic American brands.

The companies plan to file a Form S-4 registration statement with the SEC, including a joint proxy statement/prospectus, and will seek stockholder approval from both Kimberly-Clark and Kenvue investors. The communication emphasizes that investors should rely on the full registration statement and joint proxy statement/prospectus when available, and it provides standard cautionary language that forward-looking statements about expected benefits, synergies, and financial impact are subject to numerous risks, including regulatory approvals, integration challenges, transaction timing, market reactions, and broader economic and operational uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
merger
Rhea-AI Summary

Kenvue Inc.: FMR LLC filed a Schedule 13G/A (Amendment No. 3) reporting beneficial ownership of 90,322,373.80 shares of Kenvue common stock, representing 4.7% of the class. As of the event date 09/30/2025, FMR reports sole voting power over 54,101,208.75 shares and sole dispositive power over 90,322,373.80 shares. Abigail P. Johnson is also a reporting person, reflecting the same aggregate amount with sole dispositive power.

The filing is made on a passive basis, with a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes that one or more other persons have rights to receive dividends or sale proceeds for these securities, and no single such person’s interest exceeds five percent of the total outstanding common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Kenvue Inc. (KVUE) reported Q3 fiscal 2025 results. Net sales were $3,764 million versus $3,899 million a year ago, with gross profit of $2,226 million. Operating income was $629 million, and net income reached $398 million, or $0.21 per diluted share. The company recorded $17 million of Separation-related costs in the quarter and paid a cash dividend of $0.2075 per share.

For the first nine months, net sales totaled $11,344 million and net income was $1,140 million. Cash flow from operations was $1,343 million. Total debt was $8,973 million, including commercial paper of $1,160 million; Kenvue issued $750 million of 4.85% Senior Notes due 2032 in May and the 5.50% Notes due 2025 were repaid. Shares outstanding were 1,915,802,170 as of October 28, 2025. Management noted the Skin Health and Beauty unit’s fair value exceeded carrying value by about 10% in Q3; a 100 bps higher discount rate would have resulted in an impairment.

Subsequent event: On November 2, 2025, Kenvue entered into a Merger Agreement with Kimberly‑Clark Corporation, subject to customary closing conditions and regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.32%
Tags
quarterly report
-
Filing
Rhea-AI Summary

Kenvue Inc. entered into a definitive merger agreement with Kimberly-Clark. Each share of Kenvue common stock will be converted into the right to receive 0.14625 shares of K-C common stock plus $3.50 in cash, subject to closing conditions. The K-C shares issued as consideration will be listed on Nasdaq, and no fractional shares will be issued; cash will be paid in lieu of fractions.

Closing requires approvals from both companies’ stockholders, antitrust clearances, effectiveness of an S-4 registration statement including a joint proxy/prospectus, and Nasdaq listing approval for the stock consideration. The agreement includes an outside date of November 2, 2026, extendable to May 3, 2027 for certain regulatory approvals, and a $1,136,000,000 termination fee in specified circumstances. K-C will add three Kenvue designees to its board at closing. Kenvue equity awards will convert into Kimberly-Clark awards per an equity award exchange ratio, with vested RSUs receiving the merger consideration. Separately, Kirk L. Perry was appointed Kenvue’s permanent CEO with defined salary, bonus, equity awards, and a potential transaction bonus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.32%
Tags
current report
Rhea-AI Summary

Kenvue Inc. filed a current report to share that it has released financial results for its fiscal third quarter ended September 28, 2025. On November 3, 2025, the company issued a press release and accompanying prepared remarks discussing these quarterly results.

The press release is attached as Exhibit 99.1, and management’s prepared remarks as Exhibit 99.2, with the remarks also available on the company’s investor website. Kenvue is treating this earnings information as “furnished” rather than “filed,” which limits how it is incorporated into other regulatory documents under securities laws.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.32%
Tags
current report

FAQ

What is the current stock price of Kenvue (KVUE)?

The current stock price of Kenvue (KVUE) is $17.2 as of January 19, 2026.

What is the market cap of Kenvue (KVUE)?

The market cap of Kenvue (KVUE) is approximately 33.0B.
Kenvue Inc.

NYSE:KVUE

KVUE Rankings

KVUE Stock Data

32.95B
1.92B
0.04%
101.97%
2.29%
Household & Personal Products
Perfumes, Cosmetics & Other Toilet Preparations
Link
United States
SUMMIT

KVUE RSS Feed